Last updated: March 2, 2026
What Is NDC 70000-0639?
NDC 70000-0639 corresponds to Eptacog Alfa (Recombinant), a recombinant coagulation factor used in patients with hemophilia A or B experiencing bleeding episodes or perioperative management. It is marketed under the brand name Novoseven RT by Novo Nordisk.
Market Overview
Therapeutic Area and Population
Hemophilia A and B are rare inherited bleeding disorders affecting approximately 42,000 patients in the U.S. and comparable populations globally (World Federation of Hemophilia, 2021). The unmet need in controlling bleeding events remains significant, particularly for patients with inhibitors.
Current Market Size and Revenue
The global hemophilia treatment market was valued at approximately USD 9.2 billion in 2021, projected to reach USD 13 billion by 2027, expanding at a CAGR of 6.1% (Grand View Research, 2022). Eptacog Alfa, as a recombinant factor, accounts for a significant portion of this market, particularly in the bypassing agent segment for inhibitor patients.
Key Competitors
- Baxalta (now part of Takeda): Advate (recombinant factor VIII)
- CSL Behring: Hemlibra (emicizumab), a bispecific antibody
- Pfizer: Xyntha, ReFacto
- Other bypassing agents: NovoSeven (original formulation and RT)
Regulatory Status
- Approved in the U.S. since 2004.
- Approved in the EU and other regions.
Market Dynamics and Trends
Pricing Structure
- Per-vial cost: Approximately USD 2,500 to USD 4,000, depending on dosage, with weight-based dosing protocols.
- Annual treatment cost: Varies from USD 200,000 to USD 500,000 for severe hemophilia patients, influenced by disease severity, inhibitor status, and treatment regimen.
Pricing Trends
- Prices have largely remained stable but face pressure from biosimilars, emerging therapies, and value-based healthcare policies.
- Winds of change stem from increased biosimilar entry and new treatment modalities like gene therapy.
Impact of Biosimilars and Alternative Treatments
While biosimilar factor VIII products are entering some markets, the complexity and indication-specific approvals limit their immediate impact on Eptacog Alfa's pricing. The recent approval of non-factor alternatives like emicizumab shifts some patient volume toward subcutaneous regimens, impacting demand for recombinant factors.
Price Projections
Short-Term (Next 1-2 Years)
- Pricing will likely stabilize with incremental increases of 2-3% annually.
- Distribution channels and payers exert pricing controls, leading to competitive discounts in negotiated contracts.
- No imminent biosimilar threats in major markets for recombinant bypassing agents.
Mid to Long-Term (3-5 Years)
- Introduction of biosimilars in markets with feasible regulatory pathways (EU, certain Asian countries) could reduce prices by 10-15%.
- Market expansion driven by increased diagnosis and off-label use in non-inhibitor patients.
- Potential impact from gene therapy approvals, which may reduce demand for current recombinant products but could open new markets.
Estimated Price Range (2023-2028)
| Year |
Estimated Per-Vial Cost |
Observations |
| 2023 |
USD 2,500 – USD 4,000 |
Prices remain steady, limited biosimilar impact in primary markets. |
| 2025 |
USD 2,550 – USD 4,100 |
Slight increases; biosimilar entry in some regions may start. |
| 2028 |
USD 2,600 – USD 4,300 |
Biosimilar competition possible; demand shifts toward gene therapies. |
Market Entry Barriers and Opportunities
- High manufacturing costs for recombinant proteins.
- Stringent regulatory requirements.
- Increasing adoption of non-factor alternatives.
- Potential for market share gains via price reductions or expanded indications.
Regulatory and Policy Influences
- Price controls in markets like the UK and some EU nations.
- Reimbursement policies favor value-based agreements.
- Advances in gene therapy could redefine treatment paradigms.
Key Takeaways
- NDC 70000-0639 (Novoseven RT) operates in a stable, high-cost niche within the hemophilia treatment market.
- Market revenues are driven by high per-unit costs, robust demand for inhibitor management, and limited biosimilar penetration.
- Price growth is expected to remain modest short-term, with potentially more pressure if biosimilars gain acceptance or gene therapies reduce demand.
- Regulatory and policy environments will heavily influence pricing and market share trends over the coming years.
FAQs
Q1. How does the pricing of NDC 70000-0639 compare to biosimilars?
Biosimilars tend to be priced 15-30% lower than branded recombinant factors; however, biosimilar penetration varies by market and indication.
Q2. Will gene therapy affect the market for recombinant factors like Novoseven RT?
Yes, gene therapies' potential to cure or significantly reduce disease severity could decrease demand for current recombinant products.
Q3. What are the primary pricing drivers for hemophilia treatments?
Treatment costs are driven by per-unit drug prices, dosing frequency, and patient weight, compounded by healthcare reimbursement policies.
Q4. Are there regional differences in pricing for NDC 70000-0639?
Yes, prices are higher in the U.S. due to lack of price controls and more aggressive negotiation, whereas prices in Europe and emerging markets tend to be lower.
Q5. What are the main factors influencing future biosimilar entry?
Regulatory pathways, patent expiration dates, manufacturing complexity, and market acceptance impact biosimilar entry timelines.
References
[1] Grand View Research. (2022). Hemophilia treatment market size, share & trends analysis.
[2] World Federation of Hemophilia. (2021). Annual Global Survey.
[3] FDA. (2004). Approval letter for Novoseven RT.
